SCB-1022 + SCB-1033

SCB-1022 + SCB-1033 refers to the co-administration or parallel development of two investigational, recombinant subunit vaccines targeting major respiratory viruses in older adults[1][5][6][9]. - **SCB-1022** is designed as a bivalent vaccine combining prefusion RSV F protein antigens (RSV A and RSV B) with prefusion human metapneumovirus (hMPV) F protein antigen[7][12]. - **SCB-1033** extends this by adding a prefusion parainfluenza virus type 3 (PIV3) F protein antigen, making it trivalent[7][12]. Both utilize Clover Biopharmaceuticals’ Trimer-Tag platform, which stabilizes the prefusion conformation of viral F proteins, aiming for robust immunogenicity[6]. The vaccines are intended to induce strong neutralizing antibody responses against all included strains without immune interference[1][5]. Both demonstrated 6–8-fold increases in RSV nAbs and substantial rises in hMPV and PIV3 nAbs, with favorable safety profiles in Phase I studies in older adults[5][9]. Primary indication: **prevention of respiratory disease caused by RSV, hMPV, and (for SCB-1033) PIV3, in older adults**[1][5][6][9][12].

Other names

RSV+hMPV combination vaccine (SCB-1022)RSV+hMPV+PIV3 combination vaccine (SCB-1033)